Literature DB >> 21439351

Human clinical trails in antiepileptogenesis.

Ram Mani1, John Pollard, Marc A Dichter.   

Abstract

Blocking the development of epilepsy (epileptogenesis) is a fundamental research area with the potential to provide large benefits to patients by avoiding the medical and social consequences that occur with epilepsy and lifelong therapy. Human clinical trials attempting to prevent epilepsy (antiepileptogenesis) have been few and universally unsuccessful to date. In this article, we review data about possible pathophysiological mechanisms underlying epileptogenesis, discuss potential interventions, and summarize prior antiepileptogenesis trials. Elements of ideal trials designs for successful antiepileptogenic intervention are suggested.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21439351      PMCID: PMC3138332          DOI: 10.1016/j.neulet.2011.03.010

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  42 in total

Review 1.  Neurotransmitters and motor activity: effects on functional recovery after brain injury.

Authors:  Larry B Goldstein
Journal:  NeuroRx       Date:  2006-10

Review 2.  Clinical practice. Initial management of epilepsy.

Authors:  Jacqueline A French; Timothy A Pedley
Journal:  N Engl J Med       Date:  2008-07-10       Impact factor: 91.245

3.  Evaluation of postoperative sharp waveforms through EEG and magnetoencephalography.

Authors:  Jong Woo Lee; Naoaki Tanaka; Hideaki Shiraishi; Tracey A Milligan; Barbara A Dworetzky; Shahram Khoshbin; Steven M Stufflebeam; Edward B Bromfield
Journal:  J Clin Neurophysiol       Date:  2010-02       Impact factor: 2.177

Review 4.  Experimental status epilepticus in animals: What are we modeling?

Authors:  Robert S Sloviter
Journal:  Epilepsia       Date:  2009-12       Impact factor: 5.864

5.  Valproate therapy for prevention of posttraumatic seizures: a randomized trial.

Authors:  N R Temkin; S S Dikmen; G D Anderson; A J Wilensky; M D Holmes; W Cohen; D W Newell; P Nelson; A Awan; H R Winn
Journal:  J Neurosurg       Date:  1999-10       Impact factor: 5.115

6.  Risk of recurrent seizures after two unprovoked seizures.

Authors:  W A Hauser; S S Rich; J R Lee; J F Annegers; V E Anderson
Journal:  N Engl J Med       Date:  1998-02-12       Impact factor: 91.245

7.  Dissolvable films of silk fibroin for ultrathin conformal bio-integrated electronics.

Authors:  Dae-Hyeong Kim; Jonathan Viventi; Jason J Amsden; Jianliang Xiao; Leif Vigeland; Yun-Soung Kim; Justin A Blanco; Bruce Panilaitis; Eric S Frechette; Diego Contreras; David L Kaplan; Fiorenzo G Omenetto; Yonggang Huang; Keh-Chih Hwang; Mitchell R Zakin; Brian Litt; John A Rogers
Journal:  Nat Mater       Date:  2010-04-18       Impact factor: 43.841

8.  Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial.

Authors:  Nancy R Temkin; Gail D Anderson; H Richard Winn; Richard G Ellenbogen; Gavin W Britz; James Schuster; Timothy Lucas; David W Newell; Pamela Nelson Mansfield; Joan E Machamer; Jason Barber; Sureyya S Dikmen
Journal:  Lancet Neurol       Date:  2007-01       Impact factor: 44.182

9.  Risk of unprovoked seizure after acute symptomatic seizure: effect of status epilepticus.

Authors:  D C Hesdorffer; G Logroscino; G Cascino; J F Annegers; W A Hauser
Journal:  Ann Neurol       Date:  1998-12       Impact factor: 10.422

Review 10.  Molecular and diffusion tensor imaging of epileptic networks.

Authors:  Aimee F Luat; Harry T Chugani
Journal:  Epilepsia       Date:  2008       Impact factor: 5.864

View more
  19 in total

Review 1.  Prospects for imaging-related biomarkers of human epileptogenesis: a critical review.

Authors:  William A Gomes; Shlomo Shinnar
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 2.  Disease modification in epilepsy: from animal models to clinical applications.

Authors:  Melissa L Barker-Haliski; Dan Friedman; Jacqueline A French; H Steve White
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

3.  Evaluating an etiologically relevant platform for therapy development for temporal lobe epilepsy: effects of carbamazepine and valproic acid on acute seizures and chronic behavioral comorbidities in the Theiler's murine encephalomyelitis virus mouse model.

Authors:  Melissa L Barker-Haliski; E Jill Dahle; Taylor D Heck; Timothy H Pruess; Fabiola Vanegas; Karen S Wilcox; H Steve White
Journal:  J Pharmacol Exp Ther       Date:  2015-03-09       Impact factor: 4.030

Review 4.  New avenues for anti-epileptic drug discovery and development.

Authors:  Wolfgang Löscher; Henrik Klitgaard; Roy E Twyman; Dieter Schmidt
Journal:  Nat Rev Drug Discov       Date:  2013-09-20       Impact factor: 84.694

5.  New strategies for preventing epileptogenesis: perspective and overview.

Authors:  Hal Blumenfeld
Journal:  Neurosci Lett       Date:  2011-02-24       Impact factor: 3.046

Review 6.  Issues related to development of antiepileptogenic therapies.

Authors:  Asla Pitkänen; Astrid Nehlig; Amy R Brooks-Kayal; F Edward Dudek; Daniel Friedman; Aristea S Galanopoulou; Frances E Jensen; Rafal M Kaminski; Jaideep Kapur; Henrik Klitgaard; Wolfgang Löscher; Istvan Mody; Dieter Schmidt
Journal:  Epilepsia       Date:  2013-08       Impact factor: 5.864

Review 7.  Neuroimaging the epileptogenic process.

Authors:  Sandy R Shultz; Terence J O'Brien; Maria Stefanidou; Ruben I Kuzniecky
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 8.  Prevention of Epilepsy: Issues and Innovations.

Authors:  Dieter Schmidt; Matti Sillanpää
Journal:  Curr Neurol Neurosci Rep       Date:  2016-11       Impact factor: 5.081

Review 9.  Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies.

Authors:  H Steve White; Wolfgang Löscher
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 10.  Anti-epileptogenic clinical trial designs in epilepsy: issues and options.

Authors:  Dieter Schmidt; Daniel Friedman; Marc A Dichter
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.